Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2008 1
2009 2
2010 3
2011 1
2012 2
2013 3
2014 3
2015 5
2016 2
2018 1
2019 4
2020 7
2021 7
2022 4
2023 6
2024 5
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Tumour lysis syndrome.
Howard SC, Avagyan A, Workeneh B, Pui CH. Howard SC, et al. Nat Rev Dis Primers. 2024 Aug 22;10(1):58. doi: 10.1038/s41572-024-00542-w. Nat Rev Dis Primers. 2024. PMID: 39174582 Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Hypomagnesemia in the Cancer Patient.
Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Workeneh BT, et al. Kidney360. 2020 Nov 11;2(1):154-166. doi: 10.34067/KID.0005622020. eCollection 2021 Jan 28. Kidney360. 2020. PMID: 35368816 Free PMC article. Review.
Chemotherapy-related cognitive impairment and kidney dysfunction.
Simeoni M, Mulholland MM, Workeneh BT, Capasso A, Hafez G, Liabeuf S, Malyszko J, Mani LY, Trevisani F, De A, Wagner CA, Massy ZA, Unwin R, Capasso G; CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators. Simeoni M, et al. Nephrol Dial Transplant. 2025 Mar 13;40(Supplement_2):ii54-ii63. doi: 10.1093/ndt/gfae249. Nephrol Dial Transplant. 2025. PMID: 40080088 Free PMC article. Review.
Hyponatremia in the cancer patient.
Workeneh BT, Jhaveri KD, Rondon-Berrios H. Workeneh BT, et al. Kidney Int. 2020 Oct;98(4):870-882. doi: 10.1016/j.kint.2020.05.015. Epub 2020 Jun 1. Kidney Int. 2020. PMID: 32497528 Free article. Review.
63 results